Significantly Enriched Pathways. by Jiyong Zhang (2498740)

Subjects:

Health inequalities in the burden of IBD among WCBA. by Jiefeng Zhao (9090305)

Subjects:

Frontier analysis for the potential for improvement in reducing the burden of IBD among WCBA across 204 countries and regions. by Jiefeng Zhao (9090305)

Subjects:

Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

“…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

Decomposition analysis of the changes in prevalence (A), DALYs (B), and mortality (C) rates of IBD among women across global, 5 SDI and 21 GBD regions. by Jiefeng Zhao (9090305)

Subjects:

Estimated prevalence (A), DALYs (B), and mortality (C) rates for IBD among WCBA by 2040. by Jiefeng Zhao (9090305)

Subjects:

The global changes of AS prevalence, DALYs, and mortality rates of IBD among women from 1990 to 2021. by Jiefeng Zhao (9090305)

Subjects:

Estimated prevalence (A), DALYs (B), and mortality (C) rates of IBD in different age subgroups of WCBA by 2040. by Jiefeng Zhao (9090305)

Subjects:

The global changes of prevalence (A-C), DALYs (D-F), and mortality (G-I) rates of IBD among WCBA from 1990 to 2021. by Jiefeng Zhao (9090305)

Subjects:

Pre-RT and post RT D-dimer levels in associated with prognostic significance. by Huriye Senay Kiziltan (22298378)

Subjects:

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…<b>(D)</b> Similarly, U251MG cells showed significantly decreased clonogenic potential upon 100ΜM SHG-44 treatment when compared to 100ΜM cis-platin and the untreated control. …”

Trends in the burden of stroke attributed to smoking. by Jaber S. Alqahtani (8822396)

Subjects:

<i>In vivo</i> treatment decreases bacterial burden and colonization of vital organs in a skin abscess biofilm infection model. by Robert L. Beckman I.V (22784303)

Predictive Significance of Glycosyltransferase-Related lncRNAs in Endometrial Cancer: A Comprehensive Analysis and Experimental Validation by Xiaoyu Shen (4715430)

Subjects:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”